Kukjeon Pharmaceutical Co Ltd banner
K

Kukjeon Pharmaceutical Co Ltd
KOSDAQ:307750

Watchlist Manager
Kukjeon Pharmaceutical Co Ltd
KOSDAQ:307750
Watchlist
Price: 4 030 KRW 3.87% Market Closed
Market Cap: ₩217.6B

Kukjeon Pharmaceutical Co Ltd
Other

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Kukjeon Pharmaceutical Co Ltd
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
K
Kukjeon Pharmaceutical Co Ltd
KOSDAQ:307750
Other
₩2.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Other
-₩3B
CAGR 3-Years
-265%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SK Biopharmaceuticals Co Ltd
KRX:326030
Other
₩0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Other
₩1.1k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Caregen Co Ltd
KOSDAQ:214370
Other
-₩50m
CAGR 3-Years
N/A
CAGR 5-Years
15%
CAGR 10-Years
N/A
No Stocks Found

Kukjeon Pharmaceutical Co Ltd
Glance View

Market Cap
217.6B KRW
Industry
Pharmaceuticals

Kukjeon Pharmaceutical Co., Ltd. engages in providing financial support services. The company is headquartered in Anyang, Gyeonggi-Do. The company went IPO on 2018-12-19. The firm manufactures and sells raw materials used in specialized medicines such as choline alfoscerates, benfothiamines, spherical sorbents, and napamostat mesylatse. The firm sells its products in domestic and overseas markets such as Japan.

Intrinsic Value
2 215.97 KRW
Overvaluation 45%
Intrinsic Value
Price ₩4 030
K

See Also

What is Kukjeon Pharmaceutical Co Ltd's Other?
Other
2.6B KRW

Based on the financial report for Sep 30, 2025, Kukjeon Pharmaceutical Co Ltd's Other amounts to 2.6B KRW.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett